›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:NeXT Dx™ Test
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
PersonalisType:
Laboratory Developed Test
Related tests:
The Personalis NeXT Dx™ Test* is a comprehensive genomic testing solution that enables oncologists to identify potential therapies and clinical trial options for cancer patients. The NeXT Dx Test is one of the first cancer diagnostic test to profile ~20,000 cancer related genes in both tumor exome and transcriptome. The clinical report documents the genetic alterations found in 248 clinically-relevant, cancer genes, as well as research data that can provide insights into emerging immunotherapy composite biomarkers of medical importance. Single nucleotide variants (SNVs), insertions/deletions (indels), copy number alterations (CNAs), and gene fusions for targeted therapy selection, as well as tumor mutational burden (TMB) and microsatellite instability (MSI) status, are reported for immunotherapy selection.
Cancer:
Solid Tumor
Gene:
ALK (Anaplastic lymphoma kinase), ARID1A (AT-rich interaction domain 1A), ATM (ATM serine/threonine kinase), BCL2 (B-cell CLL/lymphoma 2), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset)
See More ...
ALK (Anaplastic lymphoma kinase), ARID1A (AT-rich interaction domain 1A), ATM (ATM serine/threonine kinase), BCL2 (B-cell CLL/lymphoma 2), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1), CD276 (CD276 Molecule), CHEK1 (Checkpoint kinase 1), CHEK2 (Checkpoint kinase 2), EGFR (Epidermal growth factor receptor), FANCA (FA Complementation Group A), FANCL (FA Complementation Group L), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), HER-2 (Human epidermal growth factor receptor 2), KIT (KIT proto-oncogene, receptor tyrosine kinase), KRAS (KRAS proto-oncogene GTPase), MET (MET proto-oncogene, receptor tyrosine kinase), MSI (Microsatellite instability), NRAS (Neuroblastoma RAS viral oncogene homolog), NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1), NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2), NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3), PALB2 (Partner and localizer of BRCA2), PDGFRA (Platelet Derived Growth Factor Receptor Alpha), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), RAD51B (RAD51 Paralog B), RAD51C (RAD51 paralog C), RAD51D (RAD51 paralog D), RET (Ret Proto-Oncogene), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS), TMB (Tumor Mutational Burden)
Method:
Next-Generation Sequencing (NGS)
